|
Schirdewan博士的引述的參考文獻: . m# I6 G. t7 z9 y7 e8 S: l( s) k! N
5 n* l9 K8 }1 k( Y r
Camm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009. $ ?0 g0 g! R/ ^3 l$ ^0 J. ]3 f% k$ M
$ l8 R/ m! d/ A" i* H7 U
Daubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008 4 S. E* e9 o# M/ z% w# ` P! S
" e s' U$ F1 Z9 y" A; X7 r9 W
Ricci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010. 7 e4 Q q) n+ X, o
8 {* j& u% H7 _; e) l$ K7 ~. c' U
關於BIOTRONIK SE & Co. KG
* x {& q( N& A! W5 k0 H' M5 e7 w9 T
% O& B" G' T8 c7 y: D" ]1 XBIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|